Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

budigalimab (ABBV-181)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

AbbVie

Drug class:

PD1 inhibitor

Related drugs:

‹

›

IL6 elevation	Non Small Cell Lung Cancer	IL6 elevation	Non Small Cell Lung Cancer	ABBV-181 Sensitive: C3 – Early Trials ABBV-181 Sensitive : C3	ABBV-181 Sensitive: C3 – Early Trials ABBV-181 Sensitive : C3
PD-L1 negative	Head and Neck Cancer	PD-L1 negative	Head and Neck Cancer	ABBV-181 Sensitive: C3 – Early Trials ABBV-181 Sensitive : C3	ABBV-181 Sensitive: C3 – Early Trials ABBV-181 Sensitive : C3
PD-L1 negative	Non Small Cell Lung Cancer	PD-L1 negative	Non Small Cell Lung Cancer	ABBV-181 Sensitive: C3 – Early Trials ABBV-181 Sensitive : C3	ABBV-181 Sensitive: C3 – Early Trials ABBV-181 Sensitive : C3
PD-L1 expression	Squamous Cell Carcinoma of Head and Neck	PD-L1 expression	Squamous Cell Carcinoma of Head and Neck	ABBV-181 Sensitive: C3 – Early Trials ABBV-181 Sensitive : C3	ABBV-181 Sensitive: C3 – Early Trials ABBV-181 Sensitive : C3
PD-L1 expression	Non Small Cell Lung Cancer	PD-L1 expression	Non Small Cell Lung Cancer	ABBV-181 Sensitive: C3 – Early Trials ABBV-181 Sensitive : C3	ABBV-181 Sensitive: C3 – Early Trials ABBV-181 Sensitive : C3
IL6 underexpression	Squamous Cell Carcinoma of Head and Neck	IL6 underexpression	Squamous Cell Carcinoma of Head and Neck	ABBV-181 Sensitive: C3 – Early Trials ABBV-181 Sensitive : C3	ABBV-181 Sensitive: C3 – Early Trials ABBV-181 Sensitive : C3
CSF1 underexpression	Squamous Cell Carcinoma of Head and Neck	CSF1 underexpression	Squamous Cell Carcinoma of Head and Neck	ABBV-181 Sensitive: C3 – Early Trials ABBV-181 Sensitive : C3	ABBV-181 Sensitive: C3 – Early Trials ABBV-181 Sensitive : C3
CCL23 underexpression	Squamous Cell Carcinoma of Head and Neck	CCL23 underexpression	Squamous Cell Carcinoma of Head and Neck	ABBV-181 Sensitive: C3 – Early Trials ABBV-181 Sensitive : C3	ABBV-181 Sensitive: C3 – Early Trials ABBV-181 Sensitive : C3
TMB-H	Squamous Cell Carcinoma of Head and Neck	TMB-H	Squamous Cell Carcinoma of Head and Neck	ABBV-181 Sensitive: C3 – Early Trials ABBV-181 Sensitive : C3	ABBV-181 Sensitive: C3 – Early Trials ABBV-181 Sensitive : C3
IL6 underexpression	Non Small Cell Lung Cancer	IL6 underexpression	Non Small Cell Lung Cancer	ABBV-181 Sensitive: C3 – Early Trials ABBV-181 Sensitive : C3	ABBV-181 Sensitive: C3 – Early Trials ABBV-181 Sensitive : C3
CSF1 underexpression	Non Small Cell Lung Cancer	CSF1 underexpression	Non Small Cell Lung Cancer	ABBV-181 Sensitive: C3 – Early Trials ABBV-181 Sensitive : C3	ABBV-181 Sensitive: C3 – Early Trials ABBV-181 Sensitive : C3
CCL23 underexpression	Non Small Cell Lung Cancer	CCL23 underexpression	Non Small Cell Lung Cancer	ABBV-181 Sensitive: C3 – Early Trials ABBV-181 Sensitive : C3	ABBV-181 Sensitive: C3 – Early Trials ABBV-181 Sensitive : C3
TMB-H	Non Small Cell Lung Cancer	TMB-H	Non Small Cell Lung Cancer	ABBV-181 Sensitive: C3 – Early Trials ABBV-181 Sensitive : C3	ABBV-181 Sensitive: C3 – Early Trials ABBV-181 Sensitive : C3